Genmab/$GMAB
1D1W1MYTD1Y5YMAX
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Ticker
- $GMAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,119
- Headquarters
- Copenhagen, Denmark
- Website
- www.genmab.com
Genmab Metrics
BasicAdvanced
$20B
2.70
$12.65
-
-
Price and volume
Market cap
$20B
52-week high
$35.43
52-week low
$23.62
Average daily volume
2.4M
Financial strength
Current ratio
2.457
Quick ratio
2.441
Long term debt to equity
83.28
Total debt to equity
88.518
Interest coverage (TTM)
4.96%
Profitability
EBITDA (TTM)
1,377
Gross margin (TTM)
93.03%
Net profit margin (TTM)
19.08%
Operating margin (TTM)
32.29%
Effective tax rate (TTM)
13.02%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
8.79%
Return on equity (TTM)
14.00%
Valuation
Price to earnings (TTM)
2.696
Price to revenue (TTM)
0.509
Price to book
21.57
Price to tangible book (TTM)
-39.29
Price to free cash flow (TTM)
2.421
Free cash flow yield (TTM)
41.31%
Free cash flow per share (TTM)
14.091
Growth
Revenue change (TTM)
22.26%
Earnings per share change (TTM)
-36.79%
3-year revenue growth (CAGR)
18.55%
10-year revenue growth (CAGR)
34.68%
3-year earnings per share growth (CAGR)
5.57%
10-year earnings per share growth (CAGR)
22.19%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Genmab News
AllArticlesVideos
Genmab A/S Q2 Earnings Call Highlights
MarketBeat2 weeks ago
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Business Wire1 month ago
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.